Chesson Harrell W, Ekwueme Donatus U, Saraiya Mona, Markowitz Lauri E
Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Emerg Infect Dis. 2008 Feb;14(2):244-51. doi: 10.3201/eid1402.070499.
We describe a simplified model, based on the current economic and health effects of human papillomavirus (HPV), to estimate the cost-effectiveness of HPV vaccination of 12-year-old girls in the United States. Under base-case parameter values, the estimated cost per quality-adjusted life year gained by vaccination in the context of current cervical cancer screening practices in the United States ranged from $3,906 to $14,723 (2005 US dollars), depending on factors such as whether herd immunity effects were assumed; the types of HPV targeted by the vaccine; and whether the benefits of preventing anal, vaginal, vulvar, and oropharyngeal cancers were included. The results of our simplified model were consistent with published studies based on more complex models when key assumptions were similar. This consistency is reassuring because models of varying complexity will be essential tools for policy makers in the development of optimal HPV vaccination strategies.
我们基于人乳头瘤病毒（HPV）当前的经济和健康影响，描述了一个简化模型，以估算美国12岁女孩接种HPV疫苗的成本效益。在基础参数值下，根据是否假设存在群体免疫效应、疫苗针对的HPV类型以及是否纳入预防肛门癌、阴道癌、外阴癌和口咽癌的益处等因素，在美国当前宫颈癌筛查实践背景下，接种疫苗每获得一个质量调整生命年的估计成本在3906美元至14723美元之间（2005年美元）。当关键假设相似时，我们简化模型的结果与基于更复杂模型的已发表研究一致。这种一致性令人安心，因为不同复杂程度的模型将是政策制定者制定最佳HPV疫苗接种策略的重要工具。
